文献速递乳腺MR

酰胺质子转移加权MRI区分乳腺癌HER2表达状态

Differentiation of HER2-Zero, -Low, and -Overexpressing Breast Cancer Using Amide Proton Transfer-Weighted Magnetic Resonance Imaging: A Single-center Preliminary Study.
PubMed 文献 · Acad Radiol · 2026-06-13

本研究纳入173例乳腺癌患者,探讨APTWI联合DWI对HER2零表达、低表达和过表达的鉴别价值。结果显示ADC和MTRasym_3.5ppm在HER2低表达和过表达组均显著高于零表达组。MRI定性联合定量特征的综合模型区分HER2零表达与低表达、过表达的AUC分别为0.811和0.911。

要点

  • MTRasym_3.5ppm在HER2低表达和过表达组均显著高于零表达组,可用于HER2分层。
  • MRI定性联合定量特征的综合模型鉴别HER2零表达与过表达AUC达0.911。
  • MTRasym_3.5ppm单独区分HER2低表达与过表达AUC为0.739,准确度最高。

核心结论

  • MTRasym_3.5ppm是HER2分层有前景的生物标志物,可无创优化个体化治疗策略。
  • 综合模型区分HER2零表达与低表达、过表达乳腺癌的AUC分别为0.811和0.911。
  • MTRasym_3.5ppm单独区分HER2低表达与过表达组的AUC为0.739,准确度最高。

研究设计与样本

  • 所有患者均行DWI和APTWI序列检查,提取ADC值和3.5 ppm处MTRasym值。
  • 组间比较采用单因素方差分析、Kruskal-Wallis检验或χ²检验。
  • 多因素logistic回归确定HER2状态的独立预测因素,ROC分析评估模型鉴别效能。

关键影像表现/征象

  • MRI形态学特征中,边缘和血供状况在不同HER2亚型间差异有统计学意义(均P=0.01)。
  • ADC值和MTRasym_3.5ppm值在HER2低表达和过表达组均显著高于HER2零表达组(均P<0.001)。
  • 临床特征中ER、PR、组织学分级、Ki-67指数和腋窝淋巴结状态在HER2亚型间差异显著(均P<0.05)。

诊断标准与关键数值

  • MTRasym_3.5ppm被确定为HER2亚型分层的独立预测因素。
  • MRI定性联合定量特征的综合模型区分HER2零表达与低表达乳腺癌的AUC为0.811。
  • MRI定性联合定量特征的综合模型区分HER2零表达与过表达乳腺癌的AUC为0.911。
  • MTRasym_3.5ppm单独区分HER2低表达与过表达组的AUC为0.739。

临床应用与阅片要点

  • APTWI序列可作为乳腺癌HER2表达状态无创评估的补充手段。
  • HER2零表达、低表达与过表达的鉴别可参考ADC值和MTRasym_3.5ppm值的差异。

局限性

  • 单中心初步研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To assess amide proton transfer-weighted imaging (APTWI) for identifying HER2 expression in breast cancer (BC) and to evaluate multiparametric model performance.

MATERIALS AND METHODS: This study finally included 173 BC patients who underwent MRI between July 2023 and December 2024 and received pathological examination. All participants were evaluated with diffusion weighted imaging (DWI) and APTWI sequences. Group comparisons of clinical, MRI qualitative, and quantitative features, including apparent diffusion coefficient (ADC) and magnetization transfer ratio asymmetry (MTRasym) at 3.5 ppm, were conducted using one-way ANOVA, the Kruskal-Wallis test, or the χ² test as appropriate. Multivariate logistic regression identified independent predictors of HER2 status, with receiver operating characteristic analysis assessing models' performance for subclass discrimination.

RESULTS: Clinically, estrogen receptor and progesterone receptor status, histological grade, Ki-67 index, and axillary lymph node differed significantly across HER2 subtypes (all P<0.05). In MRI analyses, morphological features, including margin and blood supply condition, varied significantly among subtypes(all P = 0.01). Quantitatively, both ADC and MTRasym_3.5ppm values were significantly higher in HER2-low and HER2-overexpressing groups than in HER2-zero (all p<0.001). MTRasym_3.5ppm was further identified as an independent predictor for stratifying HER2 subtypes. The combined model integrating MRI qualitative and quantitative features demonstrated optimal performance, with AUCs of 0.811 and 0.911 for distinguishing HER2-zero from HER2-low and HER2-overexpressing BCs, respectively. MTRasym_3.5ppm alone achieved the highest accuracy (AUC = 0.739) in differentiating HER2-low from HER2-overexpressing groups.

CONCLUSIONS: MTRasym_3.5ppm is a promising biomarker for HER2 stratification, offering a non-invasive framework to optimize personalized therapy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhan, Leng, Liu, et al. Differentiation of HER2-Zero, -Low, and -Overexpressing Breast Cancer Using Amide Proton Transfer-Weighted Magnetic Resonance Imaging: A Single-center Preliminary Study. Acad Radiol. 2026. PMID: 42288448. doi:10.1016/j.acra.2026.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。